Literature DB >> 28185529

Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.

Viveca Ritsinger1,2, Kerstin Brismar3,4, Klas Malmberg1, Linda Mellbin1, Per Näsman5, Lars Rydén1, Stefan Söderberg6, Åke Tenerz7, Anna Norhammar1,8.   

Abstract

OBJECTIVE: Adiponectin and leptin are associated with insulin resistance and cardiovascular disease. Information on the prognostic value after an acute myocardial infarction is still conflicting.
METHODS: Patients (n = 180) without known diabetes and with admission glucose of <11 mmol/L admitted for an acute myocardial infarction in 1998-2000 were followed for mortality and cardiovascular events (first of cardiovascular mortality/acute myocardial infarction/stroke/heart failure) until the end of 2011 (median: 11.6 years). Plasma adiponectin and leptin were related to outcome in Cox proportional-hazard regression analyses.
RESULTS: Median age was 64 years and 69% were male. Total mortality was 34% (n = 61) and 44% (n = 80) experienced a cardiovascular event. Adiponectin at discharge predicted cardiovascular events (hazard ratio; 95% confidence interval; 1.45; 1.02-2.07, p = 0.038), total mortality (2.53; 1.64-3.91, p < 0.001) and cancer mortality (3.64; 1.51-8.74, p = 0.004). After adjustment for age, sex, body mass index, previous myocardial infarction and heart failure, adiponectin predicted total mortality (1.79; 1.07-3.00, p = 0.027) but not cardiovascular events. High levels of leptin were associated with cardiovascular events during the first 7 years, after which the association was attenuated. Leptin did not predict total mortality.
CONCLUSION: In patients with acute myocardial infarction but without previously known diabetes, high levels of adiponectin at discharge predicted total mortality. The present results support the hypothesis that high rather than low levels of adiponectin predict mortality after acute myocardial infarction.

Entities:  

Keywords:  Acute myocardial infarction; adipokines; diabetes; prognosis

Mesh:

Substances:

Year:  2016        PMID: 28185529     DOI: 10.1177/1479164116678156

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  6 in total

1.  Adiponectin is valuable in the diagnosis of acute heart failure with renal insufficiency.

Authors:  Zhang Dai; Yan Zhang; Huiming Ye; Guoqiang Zhang; Hongwei Jin; Ziming Chen; Yihui Yao; Xuebing Tian; Jianfeng Zhou; Peihua Li; Xianming Liang; Huabing Xie; Shengxiang Ge; Zhongying Zhang
Journal:  Exp Ther Med       Date:  2018-07-23       Impact factor: 2.447

2.  The Adiponectin Paradox for All-Cause and Cardiovascular Mortality.

Authors:  Claudia Menzaghi; Vincenzo Trischitta
Journal:  Diabetes       Date:  2018-01       Impact factor: 9.461

3.  The association between serum adiponectin and 3-month outcome after ischemic stroke.

Authors:  Zengliang Wang; Bo Li; Yongxin Wang; Aisha Maimaitili; Hu Qin; Geng Dangmurenjiafu; Shuo Wang
Journal:  Cardiovasc Diabetol       Date:  2019-08-14       Impact factor: 9.951

4.  Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Authors:  Siwen Liang; Hongwei Li; Xuhua Shen; Ruifeng Liu
Journal:  J Clin Lab Anal       Date:  2019-02-19       Impact factor: 2.352

Review 5.  Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis.

Authors:  Lili Yang; Bin Li; Yuan Zhao; Zhengyi Zhang
Journal:  Lipids Health Dis       Date:  2019-12-23       Impact factor: 3.876

6.  Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Ya-Kun Liu; Qiang Liu; Xianwei Zeng; Jizong Zhao
Journal:  Cardiovasc Diabetol       Date:  2020-08-08       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.